Skip to main content

Advertisement

SpringerLink
Log in

Antihypertensive Treatment in Elderly Patients Aged 75 Years or Over

A 24-Week Study of the Tolerability of Candesartan Cilexetil in Relation to Hydrochlorothiazide

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Objective

To assess the safety and tolerability of the AT1-receptor blocker candesartan cilexetil in relation to the diuretic hydrochlorothiazide (HCTZ) in elderly patients.

Design and setting

A multicentre, double-blind, randomised, parallel group study. 32 general practice centres and 3 hospital centres in Denmark and Finland participated in this study.

Patients

185 patients aged ≥75 years with mean sitting diastolic blood pressure (DBP) of 95 to 114mm Hg.

Interventions

After a placebo run-in period of 4 to 8 weeks, patients were randomised to once daily treatment with candesartan cilexetil 8mg or HCTZ 12.5mg for 24 weeks. In both treatment groups the dosage could be doubled after ≥2 weeks [according to blood pressure (BP) response] and, if necessary, subsequently decreased if the higher dosage was poorly tolerated.

Main outcome measures

Proportion of patients with at least 1 adverse event; changes in laboratory values, electrocardiogram and BP during the double-blind treatment period.

Results

Once daily candesartan cilexetil 8 to 16mg was very well tolerated. The most common adverse events in both treatment groups were dizziness or vertigo and headache. Although the profile of adverse events was generally similar in the 2 treatment groups, it was notable that hypokalaemia and hyperuricaemia were not found in patients treated with candesartan cilexetil but occurred in 8.1 and 6.5%, respectively, of patients treated with HCTZ. At week 24, the adjusted mean changes in sitting DBP (24 hours postdose) from baseline were −12.0mm Hg [95% confidence interval (CI) −10.4 to −13.6] in patients treated with candesartan cilexetil and −11.4mm Hg (95% CI −9.3 to −13.6) in patients treated with HCTZ. The difference between treatments in favour of candesartan cilexetil was not statistically significant.

Conclusions

This study shows that antihypertensive treatment with candesartan cilexetil in elderly patients (aged ≥75 years) is well tolerated with a good safety profile and avoids the metabolic adverse effects of diuretic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Holzgreve H, Middeke M. Treatment of hypertension in the elderly. Drugs 1993; 46Suppl. 2: 24–31

    Article  PubMed  Google Scholar 

  2. Black HR. Management of hypertension in older persons. In: Izzo JL, Black HR, editors. Hypertension primer: the essentials of high blood pressure. 2nd ed. Dallas (TX): American Heart Association, 1999: 430–2

    Google Scholar 

  3. Guidelines Subcommittee. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83

    Google Scholar 

  4. Elmfeldt D, George M, Hübner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11Suppl. 2: S49–53

    PubMed  CAS  Google Scholar 

  5. Lacourcière Y, Asmar R for the Candesartan/Losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999; 12: 1181–7

    Article  PubMed  Google Scholar 

  6. Hollenberg NK, Sever PS. The past, present and future of hypertension management: a potential role for AT1-receptor antagonists. J Renin Angiotensin Aldo System 2000; 1: 5–10

    Article  CAS  Google Scholar 

  7. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 1996; 101: 83S–92S

    Article  PubMed  CAS  Google Scholar 

  8. Baglin A, Boulard JC, Hanslik T, et al. Metabolic adverse reactions to diuretics: clinical relevance to elderly patients. Drug Saf 1995; 12: 161–7

    Article  PubMed  CAS  Google Scholar 

  9. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5

    Article  PubMed  Google Scholar 

  10. Systolic Hypertension in the Elderly Program Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64

    Article  Google Scholar 

  11. Medical Research Council Working Party. The Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12

    Article  Google Scholar 

  12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64

    Article  PubMed  CAS  Google Scholar 

  13. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1994; 4: 265–71

    Google Scholar 

  14. Hansson L, Lindholm LH, Ekbom T, et al., for the STOP-Hypertension-2 study. Randomised trial of old and new anti-hypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6

    Article  PubMed  CAS  Google Scholar 

  15. McInnes GT, O’Kane KPJ, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11Suppl. 2: S75–80

    PubMed  CAS  Google Scholar 

  16. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11Suppl. 2: S85–9

    PubMed  CAS  Google Scholar 

  17. Chatelijer G, Degoulet P, Devries C, et al. Symptom prevalence in hypertensive patients. Eur Heart J 1982; 3Suppl. C: 45–52

    Article  Google Scholar 

  18. Wiklund I, Herlitz J, Johansson S, et al. Subjective symptoms and well-being differ in women and men after myocardial infarction. Eur Heart J 1993; 14: 1315–19

    Article  PubMed  CAS  Google Scholar 

  19. Ekeberg O, Klemsdal TO, Kjeldsen SE. Quality of life on enalapril after acute myocardial infarction. Eur Heart J 1994; 15: 1135–9

    PubMed  CAS  Google Scholar 

  20. Phillips PA, Hodsman GP, Johnston CI. Neuroendocrine mechanisms and cardiovascular homeostasis in the elderly. Cardiovasc Drugs Ther 1991; 4Suppl. 6.: 1209–13

    Article  PubMed  Google Scholar 

  21. Breckenridge A. Age-related effects of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol 1988; 12Suppl. 8: S100–4

    PubMed  Google Scholar 

  22. Nagano M, Higaki J, Mikami H, et al. Role of the renin-angiotensin system in hypertension in the elderly. Blood Press 1994; 3Suppl. 5: 130–3

    Google Scholar 

  23. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril and hydrochlorothiazide. Am J Hypertens 2000; 13: 504–11

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by AstraZeneca R&D, Mölndal, Sweden. Participating investigators are listed below.

Denmark: H. Bork-Rasmussen, Aabenraa, P. Bygvrå Vind, Gedser; H. Christensen, Terndrup; R. Christensen, Nyborg; U. Edelmann, Randers; M. Glise, Glostrup; P. Hildebrandt, Fredriksberg; A. Holm, Langeskov; N. J. Hornegaard, Odense; C. Jensen, Næstved; B. Kilde, Rønde; J. Klarskov, Roskilde; V. Lade, Hjørring; J. Larsen, Næstved; O. Lindegaard, Odense; F. Lyng, Ålbæk; J. Mehlsen, Fredriksberg; C. Meisler Jørgensen, Tåstrup; P. Munch-Fals, Gentofte; S. Neldam, Rødovre; J. Nielsen, Nykøbing F; P. E. Nielsen, Tistrup; A. Nørregård, Middelfart; J. Pedersen, Solrød Strand; R. Rasmussen, Aalborg; J. Reichardt, Tåstrup; M. Rishøj, Rødovre; D. Rost, Christiansfeld; M. Scheibel, Kjellerup; B. Skov Larsen, Roskilde; T. Sørensen, Værløse; C. Tuxen, Fredriksberg; H. Villadsen, Randers; O. Winkel, Slagelse; N. Winther-Pedersen, Kværndrup.

Finland: J. Bäck, Korsholm; B. Forsén, Närpes; J. Hänninen, Mikkeli; F. Koskinen, Korsholm; H. Levänen, Mikkeli; T. Rehnström, Karis; S. Strang, Korsholm.

Author information

Authors and Affiliations

  1. Rødovre Centrum, 294, 2610, Rødovre, Denmark

    Steen Neldam

  2. Närpes Health Centre, Närpes, Finland

    Björn Forsén

Authors
  1. Steen Neldam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Björn Forsén
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steen Neldam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neldam, S., Forsén, B. Antihypertensive Treatment in Elderly Patients Aged 75 Years or Over. Drugs & Aging 18, 225–232 (2001). https://doi.org/10.2165/00002512-200118030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118030-00007

Keywords

Search

Navigation